Abstract | OBJECTIVE: STUDY DESIGN: RESULTS: Success rates for both verum and placebo, were compared excluding seven patients with explained miscarriage (20/27 (74%) versus 21/30 (70%)) and without any such exclusion (20/33 (61%) versus 21/31 (68%)). The difference between the two groups was not statistically significant. CONCLUSIONS: A specific effect of intravenous immunoglobulin in primary recurrent miscarriage could not be demonstrated. These results imply the possibility of psychological influence, i.e. a placebo effect of intravenous immunoglobulin, on the outcome of pregnancy. Since success rates for both verum and placebo were in the same range as for treatment with allogeneic leucocytes, psychological effects might be responsible also for other kinds of immunotherapy for prevention of recurrent miscarriage. However, it cannot be excluded that success rates only reflect background values as reported for recurrent miscarriage patients without any treatment.
|
Authors | |
Journal | British journal of obstetrics and gynaecology
(Br J Obstet Gynaecol)
Vol. 101
Issue 12
Pg. 1072-7
(Dec 1994)
ISSN: 0306-5456 [Print] England |
PMID | 7826961
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunoglobulins, Intravenous
|
Topics |
- Abortion, Habitual
(etiology, prevention & control)
- Adult
- Double-Blind Method
- Female
- Humans
- Immunoglobulins, Intravenous
(adverse effects, therapeutic use)
- Pregnancy
- Pregnancy Outcome
|